# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lili Boulanger (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET025-SYN-TD
- Date: 1915-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odile Marchetti-Rowe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review at week 4 of risankizumab, on the day of the second infusion. **S**

## History of present illness

Ms. Boulanger had her first risankizumab infusion and intravenous iron four weeks ago without reaction and has her second infusion today. Her stools are down to two or three a day, soft, with no night-time stool, and the cramps are mild (Harvey-Bradshaw Index 5). She is on 20 mg of prednisone, falling to 15 mg this week, and has noticed a rounder face and lighter sleep. She has gained 1.6 kg with the supplements. The mycobacterial culture from her biopsies shows no growth after five weeks; the final report is due next week. She is rehearsing for her concert at the end of the month and composing most mornings. **S**

| Element | Detail |
|---|---|
| Interval change | Risankizumab dose 1 and iron infusion four weeks ago; dose 2 today |
| Activity | Harvey-Bradshaw Index 5, down from 11 |
| Prednisone | 20 mg, tapering as planned; mild sleep disturbance |
| Tuberculosis | Mycobacterial culture: no growth at five weeks |
| Work | Rehearsing for the March concert |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy improving |
| Gastrointestinal | Positive | Two or three soft stools a day; mild cramps; no blood |
| Integumentary | Negative | No rash; no yellowing of the skin |
| Endocrine | Positive | Rounder face on prednisone; no excessive thirst |
| Psychiatric | Positive | Lighter sleep on prednisone; mood better; PHQ-9 5, GAD-7 6 |

5 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs **S**
- Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect **S**
- Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction) **S**
- Cholecalciferol (vitamin D3) 1889 units oral tablet, one tablet by mouth once daily **S**
- Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisone **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 84 bpm; respirations 14/min; temperature 36.8 °C; oxygen saturation 99% on room air; weight 46.4 kg; BMI 18.1 kg/m². All vital signs are synthetic.

Hemoglobin: 11.6 g/dL (low); CRP: 8 mg/L (high); Albumin: 3.7 g/dL; ALT: 22 U/L; AST: 24 U/L; Total bilirubin: 0.5 mg/dL; Phosphate: 3 mg/dL; PHQ-9: 5; GAD-7: 6. All results are synthetic.

## Change since baseline

- Hemoglobin: 10.6 g/dL (low) at baseline, 11.6 g/dL (low) at this visit **S**
- CRP: 38 mg/L (high) at baseline, 8 mg/L (high) at this visit **S**
- Albumin: 3.3 g/dL (low) at baseline, 3.7 g/dL at this visit **S**
- ALT: 16 U/L at baseline, 22 U/L at this visit **S**
- AST: 19 U/L at baseline, 24 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Brighter; BMI 18.1 |
| Eyes | No jaundice |
| Mouth | Aphthous ulcers healed |
| Abdomen | Mild right lower quadrant tenderness; no fullness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Crohn disease, responding to risankizumab induction** (K50.80). Clinical response at week 4 (Harvey-Bradshaw Index 11 to 5) and CRP falling from 38 to 8 mg/L. Liver tests normal. With no growth on culture at five weeks, intestinal tuberculosis is even less likely. **S**
   - Second infusion today; third at week 8.
   - Continue the prednisone taper to stop in about three weeks.
   - Liver tests again at week 8 with the infusion and at week 12.
2. **Long-term risankizumab** (Z79.620). No infusion reaction or infection. **S**
   - Report fever, persistent cough, rash, jaundice, dark urine, or unusual tiredness promptly.
   - No live vaccines.
3. **Iron deficiency anemia, treated** (D50.0). Hemoglobin 10.6 to 11.6 g/dL four weeks after intravenous iron; phosphate 3.0 mg/dL, normal. **S**
   - Hemoglobin and ferritin at week 12.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptoms and Harvey-Bradshaw Index | Every visit | Completed today | 5, down from 11 (clinical response) |
| Laboratory | CRP | Every visit during induction | Completed today | 8 mg/L, down from 38 |
| Laboratory | Liver enzymes and bilirubin during risankizumab induction | Through at least week 12 | Completed today | ALT 22, AST 24, bilirubin 0.5 |
| Laboratory | Hemoglobin and phosphate after intravenous iron | Four weeks after the infusion | Completed today | Hemoglobin 11.6 g/dL; phosphate 3.0 mg/dL |
| Laboratory | Albumin and weight | Every visit | Completed today | Albumin 3.7 g/dL; weight up 1.6 kg |
| Laboratory | Mycobacterial culture of the biopsies | Final result at six to eight weeks | Up to date | No growth at five weeks; final report next week |
| Laboratory | Hepatitis B antibody after the booster | One to two months after the dose | Deferred | Not drawn today, a deviation from the plan: it was left off the order with the infusion blood tests. Rescheduled with the week-12 tests. She has no known exposure and the booster was given, so harm is unlikely; standing orders for post-vaccine antibody checks are now added at the time of the dose |
| Medication safety | Corticosteroid side effects and taper | Every visit on steroids | Completed today | Mild sleep disturbance and facial rounding; taper on schedule |
| Survey | Depression and anxiety screen (PHQ-9 and GAD-7) | At intervals | Completed today | PHQ-9 5 and GAD-7 6 |
| Laboratory | Fecal calprotectin | About three months after starting treatment | Due | At week 12 |
| Imaging | Ileocolonoscopy for endoscopic response | Six to twelve months after starting treatment | Due | In the autumn |

## Goal progress

- Reach a diagnosis, with tuberculosis excluded, within two weeks. Outcome by 1915-01-28: Ileocolonoscopy, biopsies, MR enterography, interferon-gamma release assay, and chest X-ray completed in nine days; Crohn disease diagnosed and intestinal tuberculosis made very unlikely, with the mycobacterial culture still pending. **S**
- Steroid-free clinical remission by week 12 to 16 of treatment. In progress; target 1915-04-27. **S**
- Normal CRP and fecal calprotectin by six months, and endoscopic response at six to twelve months. In progress; target 1915-10-05. **S**
- Regain weight to a BMI of 19 or more and correct iron and vitamin D. In progress; target 1915-08-03. **S**
- Perform her March concert and keep composing through treatment. In progress; target 1915-04-27. **S**

## Guideline basis

- ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025), American College of Gastroenterology
- ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025), American College of Gastroenterology
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021), International Organization for the Study of Inflammatory Bowel Diseases
- SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026), U.S. National Library of Medicine, DailyMed

## Follow-up

- Third infusion at week 8. Review at week 12, the first maintenance dose. **S**
- Next scheduled visit 1915-04-27: review at week 12, the first maintenance dose of risankizumab. **S**
